Controlling G protein signaling with new chemical tools
Direct chemogenetic control of heterotrimeric G protein signaling
['FUNDING_R21'] · BOSTON UNIVERSITY MEDICAL CAMPUS · NIH-10590217
This study is working on new tools that can help scientists turn on certain proteins in our cells that are important for many body functions and diseases, which could lead to better treatments and understanding of health issues.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON UNIVERSITY MEDICAL CAMPUS (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10590217 on ClinicalTrials.gov |
What this research studies
This research aims to develop innovative chemogenetic tools that allow precise activation of heterotrimeric G proteins, which play a crucial role in many physiological processes and are involved in various diseases. By engineering proteins to interact with specific chemical compounds, the researchers hope to manipulate G protein activity without affecting other cellular functions. This approach could lead to a better understanding of the mechanisms behind G protein signaling and its implications for health and disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from neurological or neuropsychiatric disorders that may be influenced by G protein signaling.
Not a fit: Patients with conditions unrelated to G protein signaling or those not affected by neurological or neuropsychiatric disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating neurological and neuropsychiatric diseases by providing more targeted interventions.
How similar studies have performed: While the approach of using chemogenetics is established, the specific application to directly manipulate heterotrimeric G protein signaling represents a novel and untested avenue.
Where this research is happening
BOSTON, UNITED STATES
- BOSTON UNIVERSITY MEDICAL CAMPUS — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GARCIA-MARCOS, MIKEL — BOSTON UNIVERSITY MEDICAL CAMPUS
- Study coordinator: GARCIA-MARCOS, MIKEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.